The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts.

Date publication

mars 2011

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr OUSSALAH Abderrahim , Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21251032

Résumé

Although thiopurines are considered safe in humans, they are still pregnancy FDA category D drugs. Prevention of post-operative recurrence is a challenge in clinical practice in Crohn's disease. The European Crohn's and Colitis Organisation consensus states that thiopurines should be considered in high-risk patients.

Mots clés

Attitude of Health Personnel, Azathioprine, therapeutic use, Crohn Disease, drug therapy, Drug Utilization, statistics & numerical data, Epidemiologic Methods, Female, Humans, Immunosuppressive Agents, therapeutic use, Postoperative Care, methods, Pregnancy, Secondary Prevention

Référence

Aliment. Pharmacol. Ther.. 2011 Mar;33(6):707-13